AbCellera Biologics Inc vs Citius Pharmaceuticals Inc — how do they compare? AbCellera Biologics Inc trades at $9.22 (market cap $2.99B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: AbCellera Biologics Inc is far larger — about 149.4× Citius Pharmaceuticals Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | CTXR | |
|---|---|---|
Market Cap | $2.99B | $20.01M |
Sector | Health | Health |
52-Week High | $9.76 | $1.82 |
52-Week Low | $2.78 | $0.48 |
Enterprise Value | $2.58B | $16.23M |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →